BioPlus Acquisition Corp.
BIOS · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2018 | 12/31/2017 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -8.53 | 0.00 | 0.39 | -0.05 |
| FCF Yield | -0.01% | -1.25% | -2.71% | -0.78% |
| EV / EBITDA | -5,221.43 | 467,198.03 | -20.54 | -66.25 |
| Quality | ||||
| ROIC | -1.27% | -0.00% | -23.03% | -20.57% |
| Gross Margin | 0.00% | 0.00% | 34.28% | 32.95% |
| Cash Conversion Ratio | -0.35 | 5.52 | 0.39 | 0.01 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -8.83% | -5.95% |
| Free Cash Flow Growth | -81,798.51% | 0.00% | -259.96% | 81.99% |
| Safety | ||||
| Net Debt / EBITDA | -4.15 | 460,094.67 | -5.77 | -17.67 |
| Interest Coverage | 0.00 | 0.00 | 1.89 | 1.01 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 17.45 | 14.42 |
| Cash Conversion Cycle | 0.00 | 0.00 | 27.59 | 19.54 |